세계의 색소침착장애 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 적응증별, 치료 및 치료법별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

Pigmentation Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Indication, by Treatment & Therapies, by End User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,306,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,707,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,211,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 색소침착장애 치료 시장은 2024년 67억 8,000만 달러로 평가되었고, 예측 기간 동안 CAGR 7.13%로 성장할 전망이며, 2030년에는 102억 5,000만 달러에 이를 것으로 예측됩니다.

색소침착장애는 색소침착 과잉과 색소침착 저하를 포함하고 햇볕, 유전, 염증, 호르몬 변화 등의 요인에 의해 피부 색조에 영향을 미칩니다. 이러한 질환은 미용상의 우려가 현저해지기 때문에 많은 사람들이 보다 투명하고 균일한 피부를 위해 치료를 요구하게 됩니다. 미의식이 높아지고 미용이 중시됨에 따라 외용제, 케미컬 필링, 레이저 치료, 더마 브레전 등의 치료에 대한 수요는 계속 증가하고 있습니다. 인구의 고령화, 피부 과학에 있어서 기술 혁신, 선진적인 제제 및 기기의 도입이, 시장 확대를 한층 더 뒷받침하고 있습니다. 게다가 스킨 케어에 초점을 맞춘 소비자 교육 및 제품 개척, 특히 하이드로퀴논이나 나이아신아마이드 등의 유효 성분을 포함한 크림의 급증이, 시장의 성장 궤도에 크게 기여하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	67억 8,000만 달러
시장 규모(2030년)	102억 5,000만 달러
CAGR(2025-2030년)	7.13%
급성장 부문	피부과 클리닉
최대 시장	북미

시장 성장 촉진요인

기술 진보

주요 시장 과제

치료 비용

주요 시장 동향

맞춤형 의료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 색소침착장애 치료 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 적응증별(색소침착 과도, 색소 탈실)
  • 치료 및 치료별(케미컬 필링, 피부 박리, 레이저 리서피싱, 간반)
  • 최종 사용자별(피부과 클리닉, 병원)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 색소침착장애 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 색소침착장애 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 색소침착장애 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제9장 남미의 색소침착장애 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 색소침착장애 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 제품 출시
• 합병 및 인수

제13장 세계의 색소침착장애 치료 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Zerigo Health.
• Bausch Health Companies Inc.
• Glenmark Pharmaceuticals Limited
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• CLINUVEL PHARMACEUTICALS LTD
• Strides Pharma Science Limited
• Astellas Pharma Inc.

제17장 전략적 제안

제18장 기업 소개 및 면책사항

AJY

영문 목차

영문목차

The Global Pigmentation Disorders Treatment Market was valued at USD 6.78 Billion in 2024 and is projected to reach USD 10.25 Billion by 2030, growing at a CAGR of 7.13% during the forecast period. Pigmentation disorders, encompassing hyperpigmentation and hypopigmentation, affect skin coloration due to factors such as sun exposure, genetics, inflammation, and hormonal changes. These conditions can result in noticeable cosmetic concerns, leading many individuals to seek treatment for clearer, more even-toned skin. With rising awareness and the increasing emphasis on aesthetics, demand for treatments like topical agents, chemical peels, laser therapies, and dermabrasion continues to grow. Aging populations, technological innovation in dermatology, and the introduction of advanced formulations and devices have further propelled market expansion. Additionally, a surge in skincare-focused consumer education and product development-particularly creams containing active ingredients such as hydroquinone and niacinamide-has significantly contributed to the market's growth trajectory.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.78 Billion
Market Size 2030	USD 10.25 Billion
CAGR 2025-2030	7.13%
Fastest Growing Segment	Dermatology Clinics
Largest Market	North America

Key Market Drivers

Technological Advancements

Rapid advancements in technology have greatly enhanced the effectiveness and precision of pigmentation disorder treatments. Innovations in laser-based therapies, including Q-switched, fractional, and picosecond lasers, have enabled targeted treatment of pigmented lesions with minimal risk of scarring. The adoption of Intense Pulsed Light (IPL) systems has broadened treatment accessibility for conditions such as age spots and sun-induced pigmentation. In addition, fractional radiofrequency (RF) devices that integrate microneedling with RF energy offer effective non-invasive treatment with minimal downtime. The refinement of topical formulations through nanotechnology and enhanced transdermal delivery systems has increased the potency and bioavailability of active ingredients. Cryotherapy tools with improved temperature control, along with the emergence of picosecond lasers capable of ultra-short pulse durations, have expanded therapeutic options, especially for resistant pigmentation conditions. These technological strides have collectively improved clinical outcomes and patient satisfaction across diverse skin types and indications.

Key Market Challenges

Cost of Treatment

The high cost of pigmentation treatment poses a significant challenge for broader market accessibility. Procedures such as laser therapy and combination treatment plans can be expensive, especially when multiple sessions are required for optimal results. Out-of-pocket expenses can be substantial, particularly in regions where pigmentation therapy is classified as elective and not covered by insurance. Beyond procedural fees, patients also bear the costs of consultation, follow-ups, prescription creams, and maintenance therapies. Premium skincare products designed for pigmentation disorders can be financially burdensome, and specialized treatments often involve travel to advanced dermatology centers, further escalating costs. The long-term nature of treatment, requiring consistent care and follow-up, adds to the financial strain, thereby limiting treatment adoption among cost-sensitive populations.

Key Market Trends

Personalized Medicine

The shift toward personalized medicine is transforming the treatment of pigmentation disorders. Tailored therapeutic strategies are now being developed based on individual patient factors such as genetic profile, skin type, lifestyle, and prior treatment responses. Genetic insights have enabled identification of mutations and variations linked to pigmentation irregularities, helping clinicians develop targeted therapies. Pharmacogenomic testing further refines this approach by determining the most effective drug or topical agent based on an individual's genetic makeup. Skin type-specific therapies and the integration of multimodal treatments-such as combining chemical peels with laser resurfacing-are gaining traction. Moreover, advancements in laser technology now permit customization of wavelength and energy settings based on patient-specific needs. Empowering patients with information and involving them in treatment decisions is also a key feature of this trend, contributing to improved adherence and satisfaction.

Key Market Players

• Zerigo Health
• Bausch Health Companies Inc.
• Glenmark Pharmaceuticals Limited
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Bayer AG
• CLINUVEL PHARMACEUTICALS LTD
• Strides Pharma Science Limited
• Astellas Pharma Inc.

Report Scope:

In this report, the Global Pigmentation Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pigmentation Disorders Treatment Market, By Indication:

• Hyperpigmentation
• Hypopigmentation

Pigmentation Disorders Treatment Market, By Treatment & Therapies:

• Chemical Peels
• Dermabrasion
• Laser Resurfacing
• Melasma

Pigmentation Disorders Treatment Market, By End User:

• Dermatology Clinics
• Hospitals

Pigmentation Disorders Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pigmentation Disorders Treatment Market.

Available Customizations:

Global Pigmentation Disorders Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pigmentation Disorders Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Hyperpigmentation, Hypopigmentation)
  • 5.2.2. By Treatment & Therapies (Chemical Peels, Dermabrasion, Laser Resurfacing, Melasma)
  • 5.2.3. By End User (Dermatology Clinics, Hospitals),
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Pigmentation Disorders Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Treatment & Therapies
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Pigmentation Disorders Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Treatment & Therapies
      • 6.3.1.2.3. By End User
  • 6.3.2. India Pigmentation Disorders Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Treatment & Therapies
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Pigmentation Disorders Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Treatment & Therapies
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Pigmentation Disorders Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Treatment & Therapies
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Pigmentation Disorders Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Treatment & Therapies
      • 6.3.5.2.3. By End User

7. Europe Pigmentation Disorders Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Treatment & Therapies
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pigmentation Disorders Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Treatment & Therapies
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Pigmentation Disorders Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Treatment & Therapies
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Pigmentation Disorders Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Treatment & Therapies
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pigmentation Disorders Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Treatment & Therapies
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Pigmentation Disorders Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Treatment & Therapies
      • 7.3.5.2.3. By End User

8. North America Pigmentation Disorders Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Treatment & Therapies
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Pigmentation Disorders Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Treatment & Therapies
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Pigmentation Disorders Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Treatment & Therapies
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Pigmentation Disorders Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Treatment & Therapies
      • 8.3.3.2.3. By End User

9. South America Pigmentation Disorders Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Treatment & Therapies
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pigmentation Disorders Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Treatment & Therapies
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Pigmentation Disorders Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Treatment & Therapies
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Pigmentation Disorders Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Treatment & Therapies
      • 9.3.3.2.3. By End User

10. Middle East and Africa Pigmentation Disorders Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Treatment & Therapies
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pigmentation Disorders Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Treatment & Therapies
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Pigmentation Disorders Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Treatment & Therapies
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Pigmentation Disorders Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Treatment & Therapies
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pigmentation Disorders Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Zerigo Health.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Bausch Health Companies Inc.
• 16.3. Glenmark Pharmaceuticals Limited
• 16.4. Novartis AG
• 16.5. Pfizer Inc.
• 16.6. Teva Pharmaceutical Industries Ltd.
• 16.7. Bayer AG
• 16.8. CLINUVEL PHARMACEUTICALS LTD
• 16.9. Strides Pharma Science Limited
• 16.10.Astellas Pharma Inc.

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료